Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd's Board of Directors held its 02/2025-2026 meeting on 7th August 2025 at the registered office in Indore. The Board approved the Unaudited Financial Results for the quarter ended 30th June 2025 (Q1 FY26). The Limited Review Report by the statutory auditors on these results was also taken on record. No specific financial figures, commentary on performance, or deviations were disclosed in this outcome filing.
This is a routine regulatory disclosure confirming the Board's approval of Q1 FY26 results and the auditors' limited review. No material impact on shareholders until the actual financial numbers are examined separately.